Ask AI
S. 3738

Hatch-Waxman Integrity Act of 2018

Hatch-Waxman Integrity Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sen. Hatch, Orrin G. [R-UT](R-UT)Sponsor
1 cosponsor1 R
1cosponsors1committees2actions1related bills7subjects
  1. IntroReferral

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Health, Education, Labor, and Pensions Committee
  2. IntroReferral10000

    Introduced in Senate

Hatch-Waxman Integrity Act of 2018 — Informed